News
DGAP-News: MorphoSys AG veröffentlicht Finanzergebnisse für das erste Quartal 2022
DGAP-News: Evotec SE berichtet Ergebnisse für das erste Quartal 2022 am 11. Mai 2022
COSMO VERKÜNDET ERWEITERUNG DER VEREINBARUNG MIT MEDTRONIC FÜR ELEVIEW(R) AUF ALLE LÄNDER AUSSER KANADA
DGAP-News: Einladung zu MorphoSys' Telefonkonferenz am 5. Mai 2022 zu den Ergebnissen für das erste Quartal 2022
Straumann Group verzeichnet sehr starkes erstes Quartal
DGAP-Adhoc: QIAGEN N.V.: QIAGEN erhöht Ausblick für das Gesamtjahr 2022
DGAP-HV: RHÖN-KLINIKUM Aktiengesellschaft: Bekanntmachung der Einberufung zur Hauptversammlung am 08.06.2022 in Virtuell / Bad Neustadt a. d. Saale mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
DGAP-News: BB BIOTECH AG: Etablierte Kernbeteiligungen ermöglichen einen erhöhten Investitionsgrad
Survey: International Nurses on the Front Lines of COVID-19 Care
Nearly 90% of international nurses providing care in the United States have treated COVID-19 patients, while 17% have themselves contracted the coronavirus, according to a new survey.
Conducted
QIAGEN and DiaSorin widen access to latent TB testing in the U.S. with FDA approval of QuantiFERON®-TB Gold Plus assay on LIAISON® XS
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced that the U.S. Food and Drug Administration (FDA) has approved the LIAISON® QuantiFERON®-TB Gold Plus
QIAGEN und DiaSorin erweitern Zugang zu Tests auf latente TB in den USA mit FDA-Zulassung des QuantiFERON®-TB Gold Plus Tests für LIAISON®-XS-Plattformen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) und DiaSorin (FTSE MIB: DIA) gaben heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) den LIAISON® QuantiFERON®-TB Gold
QIAGEN bestätigt Wirksamkeit seiner PCR-Tests auf SARS-CoV-2 angesichts der neuen Coronavirus-Variante B.1.1.529
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die auf Polymerase-Kettenreaktionen (Polymerase Chain Reaction, PCR) basierenden Tests des Unternehmens auch
QIAGEN reaffirms effectiveness of its SARS-CoV-2 PCR tests in light of the new coronavirus variant B.1.1.529
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the
Vifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosis
Already for the seventh consecutive year of Iron Deficiency Day, Vifor Pharma is supporting a growing international alliance including the Heart Failure Policy Network, European Kidney Health
LivaNova to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that Damien McDonald, Chief Executive Officer, will participate in discussions at the Piper
Novocure to Participate in Two Upcoming Investor Conferences
Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.
William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial
ICON Releases Environmental, Social and Governance Report
ICON plc (NASDAQ:ICLR) announced today the release of its 2020 Environmental, Social and Governance (ESG) Report. With the completion of ICON’s acquisition of PRA Health Sciences, the report
Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the phase 3 pivotal LUNAR trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with immune
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
Bronson Healthcare and Acadia Healthcare Break Ground on New Behavioral Health Hospital to Serve Southwest Michigan
Bronson Healthcare and Acadia Healthcare Company today held a virtual groundbreaking ceremony marking the beginning of construction on the new hospital that the two companies are building together
AMN Healthcare Honored in the Top 3% of Public Corporate Boards for Gender Parity
AMN Healthcare has been honored by the Women’s Forum of New York as a national leader in female corporate board representation, achieving over 50% of Board of Directors’ seats held by women, among
Charles River Laboratories to Participate in Upcoming Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including:
-
Jefferies London Healthcare Conference